The European Medicines Agency will review drugs similar to Vioxx after its withdrawal by Merck due to increased stroke and heart attack risks.
Despite previous reviews concluding no need for withdrawal, concerns remain.
Pfizer's Bextra faces scrutiny, while Celebrex's data is deemed robust.
Lawsuits against Merck are mounting, alleging heart attacks from Vioxx.
Merck's financial outlook is impacted by the recall, with earnings projections lowered.
Internal documents suggest Merck knew of Vioxx risks earlier.
Legal battles intensify as evidence of Vioxx's dangers emerges.
The future of Vioxx litigation remains uncertain amidst ongoing studies and lawsuits
